We noticed you’re blocking ads

Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Refractive Surgery: Feature Story | Nov 2010

Hyperopic Correction Across Laser Platforms

The published literature and the FDA’s postmarketing approval studies have shown essentially equivalent outcomes for treating hyperopia with the available platforms, said Steven Schallhorn, MD, in an interview with Cataract & Refractive Surgery Today.1-9


“My group performed a detailed literature analysis looking at this issue and found that the outcomes were quite similar,” Dr. Schallhorn said. “We looked at the WaveLight Allegretto Q400 [Alcon Laboratories, Inc., Fort Worth, TX], Visx Star S4 [Abbott Medical Optics Inc., Santa Ana, CA], and other platforms as well. Although none of the studies had a truly robust sample size, all showed relatively similar outcomes as far as the percentage of patients who achieved a visual acuity of 20/20 and 20/40, refractive predictability, and the percentage of patients who experienced a loss of BCVA.”

Table 1 shows a comparison of the FDA study results for hyperopic LASIK, comparing the Visx Star S4 and the WaveLight Allegretto Q400 laser platforms.

“While one laser might be slightly better in one category and vice versa, the differences were not significant,” Dr. Schallhorn said. “All of the lasers were essentially equivalent in terms of treating low-to-moderate hyperopia (< +4.50 D).” He added that, today, the upper limit of hyperopic laser treatment is +5.00 D, and many surgeons treat patients who have less than this amount.

Dr. Schallhorn emphasized that the cornea of a hyperopic patient responds differently to laser treatment than that of a myopic patient. “A +2.00 D treatment can heal fundamentally differently from -2.00 D,” he stated. “Diopter for diopter, hyperopic corrections are not as predictable compared with myopia.”

Captain (Ret.) Steven C. Schallhorn, MD, is in private practice in San Diego and is chief medical director of Optical Express. He is a consultant to Abbott Medical Optics Inc. and AcuFocus, Inc. Dr. Schallhorn may be reached at steveschallhorn@opticalexpress.com.

  1. US FDA.Technolas 217A Excimer Laser System.P990027/S004.February 25,2003. http://www.fda.gov/cdrh/pdf/p990027S004.html.Accessed November 11,2005.
  2. US FDA.Visx Star S2 and S3 Excimer Laser Systems.P930016/S012.April 27,2001. http://www.fda.gov/cdrh/pdf/p930016s012.html.Accessed November 11,2005.
  3. US FDA,WaveLight ALLEGRETTO WAVE™ Excimer Laser System.P030008.October 10,2003. http://www.fda.gov/cdrh/PDF3/p030008.html.Accessed November 11,2005.
  4. US FDA.Star S4 Excimer Laser System with Variable Spot Scanning (VSS) and WaveScan WaveFront System.P930016/S017.December 14,2004.http://www.fda.gov/cdrh/pdf/p930016s017.html. Accessed November 11,2005.
  5. Esquenazi S.Five-year follow-up of laser in situ keratomileusis for hyperopia using the Technolas Keracor 117C excimer laser.J Refract Surg.2004;20:356-363.
  6. Varley GA,Huang D,Rapuano CJ,et al.LASIK for hyperopia,hyperopic astigmatism,and mixed astigmatism: a report by the American Academy of Ophthalmology.Ophthalmology.2004;111:1604-1617.
  7. Salz JJ,Stevens CA.LASIK correction of spherical hyperopia,hyperopic astigmatism,and mixed astigmatism with the LADARVision excimer laser system.Ophthalmology.2002;109:1647-1658.
  8. Rashad KM.Laser in situ keratomileusis for the correction of hyperopia from +1.25 to +5.00 diopters with the Technolas Keracor 117C laser.J Refract Surg.2001;17:113-122.
  9. Cobo-Soriano R,Llovet F,Gonzalez-Lopez F,et al.Factors that influence outcomes of hyperopic laser in situ keratomileusis. J Cataract Refract Surg.2002;28:1530-1538.
Advertisement - Issue Continues Below
Publication Ad Publication Ad
End of Advertisement - Issue Continues Below